Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Metastatic Castration-resistant Prostate Cancer 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Radium-223 × 30 days × Clear all
NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Active not recruiting
732 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡